Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.
暂无分享,去创建一个
F. Saad | H. Scher | D. George | E. Yu | K. Fizazi | E. Efstathiou | P. Lara | K. Chi | W. Kelly | G. Mason | S. Sandhu | J. Simon | Matthew R. Smith | J. Summa | B. Espina | D. Ricci | E. Zhu | Shinta Cheng | J. Freedman | L. Snyder